Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach.
Johannes A. Langendijk,Philippe Lambin,Dirk De Ruysscher,Joachim Widder,Mike Bos,Marcel Verheij +5 more
Reads0
Chats0
TLDR
A stepwise methodology to select patients for proton therapy when the primary aim is to reduce side effects is described.About:
This article is published in Radiotherapy and Oncology.The article was published on 2013-06-01 and is currently open access. It has received 416 citations till now. The article focuses on the topics: Proton therapy & Radiation therapy.read more
Citations
More filters
Journal ArticleDOI
Radiation oncology in the era of precision medicine
Michael Baumann,Mechthild Krause,Jens Overgaard,Juergen Debus,Søren M. Bentzen,J Daartz,Christian Richter,Daniel Zips,Daniel Zips,Thomas Bortfeld +9 more
TL;DR: Two major strategies, acting synergistically, will enable further widening of the therapeutic window of radiation oncology in the era of precision medicine: technology-driven improvement of treatment conformity, including advanced image guidance and particle therapy, and novel biological concepts for personalized treatment.
Journal ArticleDOI
The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies
Richard Pötter,Kari Tanderup,Christian Kirisits,Astrid de Leeuw,Kathrin Kirchheiner,Remi A. Nout,Li Tee Tan,Christine Haie-Meder,Umesh Mahantshetty,Barbara Segedin,Peter Hoskin,Kjersti Bruheim,Bhavana Rai,Fleur Huang,Erik Van Limbergen,Max Schmid,Nicole Nesvacil,Alina Sturdza,Lars Fokdal,Nina Boje Kibsgaard Jensen,Dietmar Georg,Marianne S. Assenholt,Y. Seppenwoolde,C. Nomden,Israel Fortin,Israel Fortin,Supriya Chopra,Uulke A. van der Heide,Tamara Rumpold,Jacob Christian Lindegaard,Ina M. Jürgenliemk-Schulz +30 more
TL;DR: The EMBRACE II study is an interventional and observational multicentre study which aims to benchmark a high level of local, nodal and systemic control while limiting morbidity, using state-of-the-art treatment including an advanced target volume selection and contouring protocol for EBRT and brachytherapy, a multi-parametric brachyTherapy dose prescription protocol (clinical validation of dose constraints), and use of advanced external beam radiotherapy (EBRT) and IC/IS) techniques.
Journal ArticleDOI
Validation and Modification of a Prediction Model for Acute Cardiac Events in Patients With Breast Cancer Treated With Radiotherapy Based on Three-Dimensional Dose Distributions to Cardiac Substructures
Veerle A.B. van den Bogaard,B. D. P. Ta,Arjen van der Schaaf,Angelique B. Bouma,Astrid M. H. Middag,E.J. Bantema-Joppe,Lisanne V. van Dijk,Femke B. J. van Dijk-Peters,Laurens A. W. Marteijn,Gertruida H. de Bock,Johannes G. M. Burgerhof,Jourik A. Gietema,Johannes A. Langendijk,Johannes A. Langendijk,John H. Maduro,Anne P G Crijns +15 more
TL;DR: The importance of reducing exposure of the heart to radiation to avoid excess risk of ACEs after radiotherapy for BC is confirmed, and LV-V5 seemed to be a better predictor for ACEs than MHD.
Journal ArticleDOI
Charged-particle therapy in cancer: clinical uses and future perspectives
TL;DR: Several randomized trials of charged-particle therapies that are ongoing are reviewed, with results that will enable selective delivery to patients who are most likely to benefit from them and aspects related to radiobiology, including the immune response and hypoxia, which will need to be taken into consideration in future randomized trials to fully exploit the potential of charged particles.
Journal ArticleDOI
Nuclear physics in particle therapy: a review.
Marco Durante,Harald Paganetti +1 more
TL;DR: Research in applied nuclear physics, including nuclear interactions, dosimetry, image guidance, range verification, novel accelerators and beam delivery technologies, can significantly improve the clinical outcome in particle therapy.
References
More filters
Journal ArticleDOI
Risk of Ischemic Heart Disease in Women After Radiotherapy for Breast Cancer
Sarah C. Darby,Marianne Ewertz,Paul McGale,Anna M. Bennet,Ulla Blom-Goldman,Dorthe Scavenius Brønnum,C Correa,David J. Cutter,Giovanna Gagliardi,Bruna Gigante,Maj-Britt Jensen,Andrew Nisbet,Richard Peto,Kazem Rahimi,Carolyn W. Taylor,Per Hall +15 more
TL;DR: Exposure of the heart to ionizing radiation during radiotherapy for breast cancer increases the subsequent rate of ischemic heart disease, and the increase is proportional to the mean dose to the heart, begins within a few years after exposure, and continues for at least 20 years.
Journal ArticleDOI
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.
Christopher M. Nutting,Christopher M. Nutting,James P Morden,Kevin J. Harrington,Kevin J. Harrington,Teresa Guerrero Urbano,Shreerang Bhide,Catharine H. Clark,Elizabeth Miles,Aisha Miah,Kate Newbold,Mary Anne Lagmay Tanay,Fawzi Adab,Sarah Jefferies,Christopher D Scrase,Beng K. Yap,Roger A'Hern,M. Sydenham,M. Emson,Emma Hall +19 more
TL;DR: Sparing the parotid glands with IMRT significantly reduces the incidence of xerostomia and leads to recovery of saliva secretion and improvements in associated quality of life, and thus strongly supports a role for IMRT in squamous-cell carcinoma of the head and neck.
Journal ArticleDOI
Radiation Dose–Volume Effects in the Brain
Giovanna Gagliardi,Louis S. Constine,Vitali Moiseenko,Candace R. Correa,Lori J. Pierce,Aaron M. Allen,Lawrence B. Marks +6 more
TL;DR: No substantial evidence has shown that RT induces irreversible cognitive decline in adults within 4 years of RT, and a clear correlation has been demonstrated between the target size and the risk of adverse events for single fraction radiosurgery.
Journal ArticleDOI
Radiation dose-volume effects in the lung.
Lawrence B. Marks,Søren M. Bentzen,Joseph O. Deasy,Feng-Ming Spring Kong,Jeffrey D. Bradley,I. Vogelius,Issam El Naqa,Jessica L. Hubbs,Joos V. Lebesque,Robert Timmerman,Mary K. Martel,Andrew Jackson +11 more
TL;DR: The three-dimensional dose, volume, and outcome data for lung are reviewed in detail and it is confirmed that there is no evident threshold "tolerance dose-volume" levels and there are strong volume and fractionation effects.
Journal ArticleDOI
Long-Term Cause-Specific Mortality of Patients Treated for Hodgkin’s Disease
Berthe M.P. Aleman,Alexandra W. van den Belt-Dusebout,Willem J. Klokman,Mars B. van't Veer,Harry Bartelink,Flora E. van Leeuwen +5 more
TL;DR: The main cause of death among HD patients was lymphoma, but after 20 years, HD mortality was negligible, and the RRs and AERs of death from second primary cancers (SCs) and CVDs continued to increase after 10 years.
Related Papers (5)
Predictive modelling for swallowing dysfunction after primary (chemo)radiation: Results of a prospective observational study
Miranda E.M.C. Christianen,C. Schilstra,Ivo Beetz,Christina T. Muijs,O. Chouvalova,Fred R. Burlage,Patricia Doornaert,Phil W. Koken,C. René Leemans,Rico N. P. M. Rinkel,Marieke J. de Bruijn,G. H. de Bock,Jan L. N. Roodenburg,Bernard F. A. M. van der Laan,Ben J. Slotman,Irma M. Verdonck-de Leeuw,Hendrik P. Bijl,Johannes A. Langendijk +17 more
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.
Christopher M. Nutting,Christopher M. Nutting,James P Morden,Kevin J. Harrington,Kevin J. Harrington,Teresa Guerrero Urbano,Shreerang Bhide,Catharine H. Clark,Elizabeth Miles,Aisha Miah,Kate Newbold,Mary Anne Lagmay Tanay,Fawzi Adab,Sarah Jefferies,Christopher D Scrase,Beng K. Yap,Roger A'Hern,M. Sydenham,M. Emson,Emma Hall +19 more